Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies? Hugo Mouquet  Immunity  Volume 46, Issue 4, Pages 527-529 (April 2017) DOI: 10.1016/j.immuni.2017.04.001 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Antibody-Mediated Long-Term HIV-1 Remission Contrary to ART, an early treatment cycle including a mixture of two bNAbs for SHIV-infected macaques can lead to sustained virological control regardless of the challenge route (intrarectal or intravenous). CD8+ T cell responses induced by bNAb immunotherapy are responsible for viraemia suppression in animals controlling the infection (Nishimura et al., 2017). A theoretical scenario that can be envisioned in HIV-1-infected humans is that prolonged ART combined with bNAb infusions started early in the acute phase could augment the chances of reaching a PTC phenotype after ART is stopped. Immunity 2017 46, 527-529DOI: (10.1016/j.immuni.2017.04.001) Copyright © 2017 Elsevier Inc. Terms and Conditions